Company ProfilePremium

Newbridge Acquisition Limited

Company Profile Analysis

Ticker: NBRGU

ESOMAR 23 Corporate BadgeISO Certifications Badge
Newbridge Acquisition Limited - Company showcase

Year Founded & Workforce

2021

2 Employees

Newbridge Acquisition Limited logo

Newbridge Acquisition Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Newbridge Acquisition Limited Overview

Newbridge Acquisition Limited is a small-cap, Hong Kong-managed blank-check company that raised $57.5 million in a Nasdaq IPO closed on 2 February 2026. The structure is one Class A share plus one right to one-eighth of a share per unit, with 100% of IPO proceeds placed in trust at $10.00 per public share. Its stated hunting ground was small-cap businesses in North America, Europe and Asia-Pacific. The target sectors were green and sustainable businesses, new energy, frontier technology, AI applications, business software and healthcare products. The sponsor, Wealth Path Holdings, is fronted by serial SPAC executive Yongsheng Liu, who previously led Wealthbridge (merged with Scienjoy) and Goldenbridge (merged with SunCar). Within six months of listing, the company first signed non-binding MOUs with HKEX-listed Starcoin Group, then pivoted to a definitive $1.0 billion equity-value merger with Startech Group Inc. Startech is an early-stage, US-based company combining an "aquaporin functional water" product line with an AI agent operating system called StarOS. NBRG's investment case now depends almost entirely on the quality, audited financials and redemption outcome of that transaction.


What the company does. NBRG has no operating business. It was formed to complete a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. Its only assets are the trust account and a small operating cash balance. Its only income is interest on trust investments in US Treasury bills (maturity of 185 days or less) or qualifying Rule 2a-7 Treasury money-market funds. Its only expenses are formation, administrative, legal, audit and listing costs. (Source: audited balance sheet notes, 2 February 2026.)

Company's own description (paraphrased from filings). The company describes itself as a blank-check company incorporated in the BVI to effect a business combination. It says it had not commenced operations and will not generate operating revenue until after an initial business combination at the earliest. Non-operating income will come from interest on trust-account investments. The IPO prospectus summary (as reproduced by Renaissance Capital) states that the company may pursue a target in any industry. It intended to focus on green and sustainable businesses, new energy, cutting-edge technologies, AI applications, business software and healthcare products, and on "small cap" companies domiciled in North America, Europe and/or APAC.

Business model and "revenue model". There is no revenue model; product, service, subscription and licensing mix are all 0%. The economic model of the SPAC is:

Value-chain position, customers and end-markets. Not applicable to NBRG itself. Post-closing, the combined company would take on Startech's announced position:

  • Startech's description (paraphrased from the 3 August 2026 8-K and press release): Startech calls itself a US-based AI technology company with fintech-enablement capabilities. It operates through two complementary segments. AQP Water is a functional-water business based on aquaporin-related positioning; it is expected to earn contractual per-bottle technology and settlement-service fees tied to product sales and digital product management. StarOS is an "agent operating system" for the AI era, expected to earn revenue from AI-enabled software and platform services. The press release separately describes Startech as an emerging life-sciences technology company developing functional water and AI-powered healthcare technologies aimed at health and longevity.

Independent characterization: Startech's disclosed model is a hybrid with little evident operating overlap. The AQP Water revenue description (per-bottle technology and settlement fees, not product sales) suggests an asset-light, royalty- or platform-like position. Startech appears to sit between a bottler/brand and the consumer as a technology, traceability and payment-settlement layer, which is what "fintech-enablement" likely refers to. StarOS is a software platform play in a crowded field. The combination of a consumer beverage line, "fintech-enablement", healthcare longevity claims and an AI agent OS is an unusually broad thematic mix for a company valued at $1.0 billion. As of this date, no revenue, customer, unit-volume or audited financial data for Startech has been publicly disclosed. The BCA required Startech to deliver audited financial statements for its fiscal year ended 30 June 2026 within 60 days of signing, i.e. by about 2 October 2026.

Strategy

Stated strategy (themes from the IPO prospectus, paraphrased).

  1. Sector focus: green and sustainable business, new energy, cutting-edge technologies, AI applications, business software and healthcare products, with no binding industry restriction.

  2. Size focus: "small cap" targets.

  3. Geographic focus: companies domiciled in North America, Europe and/or APAC that are developing assets across Asia, Europe and North America, drawing on management's experience with emerging start-ups.

  4. Value proposition: management's cross-border M&A record across Wealthbridge/Scienjoy and Goldenbridge/SunCar.

Strategic initiatives in the last 24 months.

Sustainability/ESG commitments, cost programs, transformation programs: None disclosed (not applicable to a shell).

Medium-term financial targets / guidance: None from NBRG. No Startech projections, investor presentation or valuation bridge had been publicly filed as of the dossier date. Projections, if any, would normally appear in the S-4 "Certain Projected Financial Information" section.

Products & Services

NBRG: Not applicable. A blank-check company has no products or services. Its listed "products" are its three securities:

Startech (prospective post-closing portfolio). Startech has disclosed product categories only, without product-level detail:

Analyst note: There is no product-level disclosure (SKUs, volumes, distribution, regulatory status of health claims, StarOS customer count or version history). The Form S-4 is the first document expected to contain it.

Product Portfolio

SecurityTickerTermsLaunchSource

Units

NBRGU

One Class A ordinary share plus one right; $10.00 offer price

Trading from 30 Jan 2026

Loeb & Loeb; 8-K

Class A ordinary shares

NBRG

No par value; redeemable from trust at the pro-rata amount (initially $10.00) in connection with a business combination or liquidation

Separate trading from ~Mar 2026

8-K; aggregators

Rights

NBRGR

Each right converts into 1/8 Class A share at closing of a business combination; no cash settlement; expires worthless on liquidation; no fractional shares issued

Separate trading from ~Mar 2026

Audited BS notes

SegmentOfferingDescriptionKey specsTarget customerLaunch / versionPricing modelFlagship names

AQP Water

Aquaporin functional water

Functional water product line positioned for health and longevity

—

Consumers (direct and/or via bottling and retail partners; not specified)

—

Per-bottle technology and settlement-service fees

"AQP Water" (segment name)

AQP Water

Digital product management

Digital layer linked to product sales (likely traceability, settlement and fintech-enablement; not specified)

———

Embedded in per-bottle fees

—

StarOS

StarOS agent operating system

Platform for AI agents, described as an operating system for the AI era

—

Not publicly disclosed (enterprise or developer, unclear)

—

AI software and platform services

"StarOS"

Healthcare AI

AI-powered healthcare technologies

Mentioned in the press release as part of Startech's longevity focus

—————

“—” = not publicly disclosed.

Financial Narrative

Context. NBRG's financial statements are those of a shell. Through FY2025 the balance sheet consisted of sponsor-funded cash and deferred offering costs. From 2 February 2026 it is dominated by the trust account. Most operating-company metrics (gross profit, EBITDA, margins, ROIC, cash conversion cycle) are zero, undefined or not meaningful. They are shown as such rather than omitted.

Income statement (USD)

Sources: FY2024–FY2025 from FY2025 10-K as rendered by app.edgar.tools (EDGAR XBRL-derived). EBITDA equals operating loss because there is no depreciation or amortization. EPS conflict: ROIC.ai shows basic EPS of -0.02 (FY2024) and -0.03 (FY2025) on a different share base. The EDGAR-derived figures are preferred.

Interim (most recent):

Source: Q2 2026 Form 10-Q (fxbaogao summary). Trust income for about five months on roughly $57.5M implies an annualized yield of about 3.3%, consistent with short-dated Treasury yields in 2026 (analyst calculation).

Margins and growth

Margins are undefined (zero revenue). Revenue CAGR is not applicable. Operating cost growth FY2025 vs FY2024 is analyst-calculated: 221,014 / 140,962 − 1 = 56.8%, driven by IPO preparation in 2025.

Balance sheet (USD)

Sources: FY2025 total assets and equity from 10-Q comparative balance sheet (fxbaogao summary) and app.edgar.tools. Total liabilities FY2025 is analyst-derived as total assets minus equity (no temporary equity existed pre-IPO). Deferred offering costs from app.edgar.tools. The $4.8M pre-IPO asset base, against $3.55M of sponsor notes at the IPO date, indicates the sponsor pre-funded cash ahead of the January 2026 closing (analyst inference).

Post-IPO balance sheets (USD):

Sources: audited balance sheet as of 2 Feb 2026 (8-K, 5 Feb 2026); Q2 2026 10-Q (fxbaogao). Note: the $58,979,103 trust figure at 2 Feb 2026 includes $1,479,097 that was released to the operating account on 3 Feb 2026. Net trust is therefore about $57.5M. Temporary equity of $51.3M is below the $57.5M redemption value because of the allocation of proceeds to rights and offering costs at initial recognition.

Cash flow (USD)

Source: FY2025 operating cash flow per app.edgar.tools. That figure equals net loss, which suggests the aggregator may have mapped it imprecisely; treat with caution.

Source: Q2 2026 10-Q (EDGAR XBRL as surfaced by search; fxbaogao). The $200,000 "proceeds from a third party" in H1 2026 is not explained in the sources reviewed. It should be examined in the full 10-Q, since it may relate to target-side funding or a working-capital arrangement.

Ratios

Commentary. NBRG's financial trajectory follows the standard SPAC lifecycle. From 2021 to 2024 it was a low-cost dormant shell. In FY2025, IPO-preparation costs rose 57% and sponsor pre-funding produced a $4.8M asset base against a shareholders' deficit. On 2 February 2026 the balance sheet stepped up roughly 12x to $60.8M when the trust was funded. The H1 2026 swing to net income ($385K) came entirely from trust interest. The one notable inflection is the auditor's going-concern paragraph at IPO, which cited a $1.77M working-capital deficit driven by the $3.55M sponsor note. That deficit was partly cured by the $1.48M release and $0.80M note repayment in early February 2026. Remaining sponsor loans and transaction costs will compete with the post-redemption trust balance at closing. Trust interest will continue to accrue at roughly $160–170K per month at current Treasury yields (analyst estimate), giving modest per-share accretion to the redemption value. That accretion matters for redemption arbitrage.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (USD)

MetricFY2023FY2024FY2025

Single segment revenue (USD)

000

Single segment formation and operating costs (USD)

—140,962221,014

Single segment net loss (USD)

—-140,962-221,014

Share of total revenue (%)

000

Revenue by Segment (USD) (Half-Yearly)

MetricH1 2025H1 2026

Net income (loss) (USD)

-88,605385,352

Trust income (USD)

0785,569

Net cash used in operations (USD)

-88,605-400,217

Group Entities

EntityJurisdictionRoleStatus

Wealth Path Holdings Limited

BVI

Sponsor; holds 1,437,500 Class B founder shares and 186,250 private units

Current

Newbridge Acquisition Limited

BVI, becoming Delaware

Listed SPAC ("Parent"), to be renamed Startech Inc. ("Pubco")

Current

NBRG Merger Sub, Inc.

Delaware

Wholly owned merger subsidiary; will merge into Startech

Formed for the transaction

Startech Group Inc.

Delaware

Target; becomes the surviving corporation and a wholly owned subsidiary of Pubco

Pending

Segment Overview

SegmentContents (as described)Intended revenue model

AQP Water

Aquaporin functional water products and digital product management

Contractual per-bottle technology fees and settlement-service fees linked to product sales

StarOS

"Agent operating system" AI platform

AI-enabled software and platform services

Income Statement (USD) and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (USD)

00000

Gross profit (USD)

00000

Formation and operating costs (USD)

———140,962221,014

Operating income (USD)

———-140,962-221,014

EBITDA (USD)

———-140,962-221,014

Trust interest income (USD)

00000

Pre-tax income (USD)

———-140,962-221,014

Net income (USD)

———-140,962-221,014

EPS basic (USD)

———-0.05-0.14

EPS diluted (USD)

———-0.05-0.14

Dividends per share (USD)

00000

Income Statement (USD)

MetricH1 2025H1 2026

Trust interest income (USD)

0785,569

Net income (loss) (USD)

-88,605385,352

Margin Analysis (%)

MetricFY2025

Operating cost growth YoY (%)

56.8

Balance Sheet (USD)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (USD)

————4,819,641

Deferred offering costs (USD)

———85,787295,399

Cash held in trust (USD)

00000

Total liabilities (USD)

————5,414,763

Shareholders' equity (USD)

————-595,122

Goodwill and intangibles (USD)

00000

Financial Analysis

Line item2 Feb 2026 (audited, IPO date)30 Jun 2026 (unaudited)

Cash outside trust

1,820,043—

Cash and marketable securities held in trust

58,979,103

Not separately verified (trust purchases of $54,800,000 in Treasuries recorded in H1 2026)

Total assets

60,799,14659,928,357

Promissory note – related party

3,552,263 (of which $804,976 repaid 3–4 Feb 2026)

—

Accrued offering costs

37,399—

Total liabilities

3,589,662—

Class A shares subject to redemption (temporary equity)

51,342,131 (5,750,000 shares)

—

Additional paid-in capital

6,462,4754,409,850

Accumulated deficit

(620,122)(234,770)

Total shareholders' equity

5,867,3534,200,080

Cash Flow (USD)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (USD)

————-221,014

Capex (USD)

00000

Free cash flow (USD)

————-221,014

Dividends paid (USD)

00000

Buybacks (USD)

00000

Returns & Leverage Ratios (USD)

MetricH1 2025H1 2026

Net cash used in operating activities (USD)

-88,605-400,217

Purchase of investments held in trust (USD)

0-54,800,000

Proceeds from public offering (USD)

057,500,000

Proceeds from private placement (USD)

01,862,500

Proceeds from a third party (USD)

0200,000

Net change in cash (USD)

-2,782-181,454

Returns & Leverage Ratios (%)

RatioFY2024FY202530 Jun 2026Comment

ROE

n/m

n/m (negative equity)

n/m

Shell

ROA

n/m

-4.6%

n/m

Analyst calc: −221,014 / 4,819,641

ROIC

n/m

n/m

n/m

No invested operating capital

Debt / equity

n/m

n/m (negative equity)

—

Debt consists of sponsor promissory notes only

Net debt / EBITDA

n/m

n/m

n/m

Negative EBITDA

Interest coverage

n/m

n/m

n/m

Sponsor notes are non-interest bearing

Asset turnover

000

No revenue

Geographic Revenue

RegionFY2023FY2024FY2025

Americas revenue (USD)

000

EMEA revenue (USD)

000

APAC revenue (USD)

000

Dimension Details

DimensionLocationRelevance

Management and sponsor base

Hong Kong / PRC (sponsor contact number has a +86 PRC prefix)

Possible PRC-related disclosure requirements, and possible CFIUS-type sensitivity for US targets if the sponsor is foreign-controlled (to be assessed in S-4)

Incorporation

BVI, moving to Delaware

Domestication changes the tax and governance regime

Trust assets

United States (US Treasuries; Equinity Trust)

Same per-share redemption claim regardless of geography

Target

United States (Delaware; "U.S.-based" per 8-K)

Post-closing revenue geography not disclosed

Abandoned MOU counterparties

Hong Kong (Starcoin Group, HKEX 0399); Panama (Conflux Foundation)

Shows the sponsor's original deal-sourcing orientation toward Greater China and digital assets

Share Price

MetricFY2026 YTD

NBRG share price, period end or latest (USD)

10.00

NBRGU unit price, latest observed (USD)

10.18

Capital Markets

ItemDetail

Analyst consensus

None (no sell-side coverage identified)

Dividend history and policy

None; no dividends expected before a combination

Buyback authorizations

None (redemptions are the functional equivalent)

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

Sponsor promissory notes are non-interest bearing and repayable on IPO closing or business combination. Extension loans (if drawn) are repayable at closing. Up to $1.5M of working-capital loans are convertible into units at $10.00.

Analyst Conclusions

Management guidance: None (SPAC). Consensus growth expectations: None.

Bull case

  1. Fast execution by an experienced sponsor. A definitive $1.0B deal within six months of IPO, led by a principal with two completed de-SPACs, improves the odds the deal reaches a vote before the about-2-May-2027 initial deadline without extension costs.

  2. Asymmetric payoff for public holders. Redeemable shares (floor at about $10.00 plus interest) plus rights (1/8 share each at no cost) give public holders downside protection with optional upside if the AI narrative attracts post-closing demand.

  3. Thematic fit. If the S-4 shows real StarOS revenue and validated AQP Water contracts, an AI-platform company with a recurring per-bottle fee stream could command a premium.

Bear case

  1. Valuation unsupported by disclosure. $1.0B equity value for a company with no public revenue, customers or audited numbers at signing is the central risk. It points to high redemptions and post-closing price pressure.

  2. Weak deal coherence and sourcing history. The sponsor moved from a Hong Kong pharma/blockchain counterparty (Starcoin/Conflux) to an AI-plus-functional-water company within months. That raises questions about target selection and the depth of diligence.

  3. Thin cash delivery and governance concerns. At high redemptions, the combined company may receive only single-digit millions of cash. Sponsor notes, transaction costs and a 92%+ insider-controlled, possibly dual-class structure would weaken minority-shareholder protection.

Key catalysts and monitorables (next 12 months)

Analyst verdict. Newbridge Acquisition Limited is, today, a $57.5 million trust account wrapped in a listing, plus an option on a single transaction. Its standalone fundamentals are those of any well-structured small SPAC. It has a 100%-funded trust at $10.00, a low 1.5% underwriting fee, positive carry from Treasury yields, and a sponsor principal with a real record of closing cross-border de-SPACs. The shell itself carries the usual blemishes: an IPO-date going-concern paragraph, meaningful sponsor debt, a combined chair and CEO who runs parallel vehicles, and several drafting inconsistencies in the IPO-date financial notes. None of these is unusual for the category, but together they suggest administrative thinness. The decisive variable is Startech Group. The $1.0 billion equity value was announced before any Startech revenue, customer, product-level or audited financial information was public. The business mixes a functional-water fee model, "fintech enablement", longevity healthcare and an AI agent operating system. That breadth reads more like a thematic assembly than an integrated operating company, and the deal followed abandoned MOUs with an HKEX-listed pharma and blockchain counterparty. Until the S-4 is filed, Startech cannot be valued on fundamentals. For public NBRG holders, the rational stance is to treat the shares as a trust-value instrument and the rights as the free option. Redemption at the vote is the default unless the S-4 discloses substantive audited revenue, credible contracts behind the per-bottle fee stream, an independent board, and committed new capital. For anyone considering the post-closing equity, the bar should be high. Expect pressure from redemptions, a small free float, and the lock-up release of founder shares after six months. Overall assessment: structurally sound shell, speculative and under-disclosed target. The investment merits of the combination cannot be determined until Startech's audited financials and the S-4 are public.


Sources consulted (all accessed 11 Oct 2026)

  • SEC EDGAR, Newbridge Acquisition Ltd (CIK 0001918414): Form 8-K/425 dated 3 Aug 2026 (accessions 000121390026084680 and 000121390026084686) including Ex. 99.1 press release; Form 8-K Ex. 99.1 audited balance sheet as of 2 Feb 2026 (accession 000121390026012753); Form 8-K re IPO (accession 000121390026010805); Form 10-Q Q2 2026 (accession 000121390026086733); Form 10-Q Q1 2026 (accession 000121390026054485); POS462C (accession 000121390025101203)

  • Loeb & Loeb LLP, news item on Newbridge's $57.5M IPO (Feb 2026)

  • Renaissance Capital, NBRGU IPO profile; IPOScoop, Newbridge Acquisition and Goldenbridge Acquisition profiles; SPAC Research, NBRGU symbol page

  • Starcoin Group (HKEX: 0399) MOU announcements, via Tiger Brokers news and Minichart (Feb–Mar 2026)

  • MarketScreener insider profile, Yong Sheng Liu; SunCar Technology Group board biography, Yongsheng Liu

  • StockTitan summaries of 8-K/425 (Aug 2026); fxbaogao summary of the Q2 2026 10-Q; Webull summary of the FY2025 10-K

  • Data aggregators (secondary, used only where flagged): app.edgar.tools, ROIC.ai, Stoxray, FinancialContent, OptionsAnalysisSuite, OpenCapital, dividend.watch

  • Independent commentary: remio.ai, "Newbridge Acquisition–Startech Merger Tests an AI and Functional Water Pitch" (Aug 2026); mg21.com Startech profile

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationCompensation

Yongsheng Liu

Chairman and Chief Executive Officer

Since 2021

Chairman/CEO, Bridge III Acquisition (since 2023); Chairman/CEO, Goldenbridge Acquisition (2020–2022; combined with SunCar Technology); COO, Goldenstone Acquisition (2021–2023); Chairman/CEO, Wealthbridge Acquisition (2018–2020; combined with Scienjoy in May 2020); Vice Chairman, Scienjoy (since 2020); Independent Director, SunCar Technology Group (since 2023); Director, AgiiPlus Global; Chairman/CEO, Royal China Holdings (HKEX: 1683) (2017–2018); CEO and Executive Director, Hope Life International (2017–2018); Chairman, Joy Air and Cambodia Bayon Airlines (2013–2017); President, General Aviation Investment (Shanghai); CSO, United Eagle / Chengdu Airlines (2004–2008); Manager, China Southern Airlines (1994–2000)

Master's, University of Ottawa (2002); Bachelor's, Civil Aviation University of China (1992)

No salary, bonus or stock compensation from the SPAC disclosed in sources reviewed. Economic interest is through the sponsor's founder shares and private units.

Chief Financial Officer

Not identified in sources reviewed

————

Governance Overview

AttributeDetail

Board members (names)

Other directors were not identified in sources reviewed; see the FY2025 10-K, Part III

Chair/CEO separation

Not separated: Yongsheng Liu is both Chairman and CEO

Post-closing board (per BCA)

Seven members. The sponsor designates one; Startech designates the remaining six. A majority must be independent. Startech's executive management becomes Pubco management.

Major Shareholders

HolderShares% of 7,546,250 outstandingBasis

Wealth Path Holdings Limited (sponsor): Class B founder shares

1,437,50019.0%

Audited BS notes

Wealth Path Holdings Limited: Class A shares in private units

186,2502.5%

Audited BS notes

Sponsor total

1,623,750

21.5%

Analyst sum

Kingswood and designees (representative shares)

172,500 (Note 7) or 150,000 (Note 6)

2.3% or 2.0%

Audited BS notes (internal discrepancy)

Public holders (Class A subject to redemption)

5,750,00076.2%

Audited BS notes

Top 10 institutional holders

Small SPACs of this type are typically held by SPAC-arbitrage funds.

——

Competitive Landscape

Key Competitors

#Competitor (SPAC / route)RelationshipRelative positioning
1

Bridge III Acquisition Ltd.

Sister SPAC with the same Chairman/CEO (Yongsheng Liu)

Potential competition for the sponsor's attention and targets

2

Goldenstone Acquisition Ltd.

Former role of Liu (COO 2021–2023)

Same sponsor-network deal flow

3

Other Kingswood-led small-cap rights SPACs

Same underwriter ecosystem

Competing for the same arbitrage-fund investor base

4

Other Hong Kong/PRC-sponsored Nasdaq SPACs ($50–75M trust)

Direct peer group

Compete for Greater China and Asia-linked targets

5

Direct small-cap Nasdaq IPOs

Alternative route for targets

Often cheaper for targets with real revenue

6

HKEX listing / HKEX SPAC regime

Alternative route

Relevant to Starcoin-type targets

7

Reverse mergers into existing Nasdaq shells

Alternative route

Lower cost, no trust

8

Private capital (VC/PE growth rounds)

Alternative to listing

Competes on valuation certainty

Competitive Advantages & Vulnerabilities

ArenaCompetitive set (illustrative categories and well-known participants)Startech positioningVulnerability

Functional and enhanced water

Large beverage majors' functional-water brands; premium, alkaline, hydrogen and electrolyte water brands; direct-to-consumer wellness beverage start-ups

Claims a technology and settlement-fee model rather than brand ownership; "aquaporin" positioning

No disclosed volumes, distribution or scientific validation; health-claim regulatory exposure (FDA/FTC)

AI agent platforms ("agent OS")

Hyperscaler agent frameworks; enterprise CRM/ITSM agent platforms; frontier-model providers' agent tooling; open-source agent frameworks

StarOS described as an agent operating system

Very crowded field dominated by heavily capitalized incumbents; no disclosed customers

Fintech enablement / settlement

Payment processors and product-traceability platforms

Settlement-service revenue per bottle

Unclear licensing and regulatory status

Recent Developments

All identifiable events are listed.

Leadership changes, guidance revisions, litigation, regulatory actions, layoffs:* None identified.

Company Snapshot

2

Employees

2021

Founded

Wanchai, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Fully funded trust. $57.5M placed in trust at $10.00 per public share, 100% of IPO proceeds (8-K, Feb 2026; SPAC Research).
  • Low IPO cost. 1.5% cash underwriting fee ($862,500); total transaction costs $1,557,894 (audited BS notes).
  • Speed to deal. Definitive BCA signed 3 August 2026, six months after IPO close and well inside the 15-month initial window ending about 2 May 2027 (8-K).
  • Experienced sponsor principal. Yongsheng Liu completed Wealthbridge/Scienjoy (2020) and Goldenbridge/SunCar de-SPACs (MarketScreener; SunCar biography).
  • Positive carry. H1 2026 trust income of $785,569 exceeded operating costs, producing $385,352 net income (Q2 2026 10-Q).
  • Aligned support. The sponsor is contractually bound to vote for the deal and any extension (Parent Support Agreement, 3 Aug 2026).

Weaknesses

  • Going-concern doubt at IPO, with a $1,769,619 working-capital deficit (audit report, 5 Feb 2026).
  • Material sponsor debt. $3,552,263 sponsor note at IPO date, of which only $804,976 was repaid in early February (audited BS notes).
  • Small trust relative to a $1.0B target valuation. The maximum $57.5M cash contribution is about 5.7% of headline equity value (analyst calculation).
  • Filing inconsistencies. Representative shares stated as 150,000 vs 172,500; a "Cayman Islands law" reference in a BVI company's notes; the subsequent-events note says no target discussions had begun, yet an MOU followed three weeks later (audited BS notes).
  • Chair/CEO roles combined, and the CEO concurrently leads another SPAC, Bridge III (MarketScreener).
  • Thin target disclosure. No Startech revenue, customers or audited financials were public at signing (8-K; independent commentary).

Opportunities

  • AI thematic premium. StarOS gives the combined company an AI narrative in a market receptive to such stories (8-K description).
  • Asset-light model if AQP Water's per-bottle fee structure works as described (8-K).
  • Rights upside. Each right delivers 1/8 share at closing at no cost, which gives public holders optionality (audited BS notes).
  • Kingswood right of first refusal could support a PIPE or post-closing capital raise (audited BS notes).
  • Delaware domestication may broaden the US institutional investor base (8-K).
  • Extension capacity to about 2 November 2027 provides time to finish the S-4 (audited BS notes; BCA Outside Date).

Threats

  • High redemptions. At 90% redemptions, only about $5.8M of trust cash would be delivered (analyst illustration).
  • SEC review risk under the 2024 SPAC rules, given the novel AI-plus-water combination and the $1.0B valuation (regulatory context).
  • Audit-delivery risk. Startech's audited FY2026 statements were due about 2 October 2026; delivery is unconfirmed (8-K covenant).
  • Nasdaq initial listing standards for the combined company, a condition to closing (8-K).
  • Reputational overhang from the abandoned Starcoin/Conflux MOUs and scrutiny of the deal's coherence (Starcoin announcements; remio.ai).
  • Liquidation risk. If no deal closes by about 2 November 2027, rights expire worthless and founder shares lose their value (audited BS notes).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 May 2025New sponsor loan agreement (cap $1.0M)Pre-IPO funding
May 2025Share reclassification into Class A/B; authorized capital resetIPO-ready capital structure
29 Aug 2025Initial registration statement filedIPO process starts
25 Sep 2025Amended registration statement filedResponds to SEC process
30 Sep 2025Registration declared effectiveIPO not launched immediately
15 Nov 2025Sponsor loan capacity raised to $5.0MSignals higher pre-IPO cash needs
18 Dec 2025Post-effective amendment declared effectiveClears the way to price
29 Jan 2026IPO priced at $10.00/unit, 5.0M unitsBase deal $50M
30 Jan 2026NBRGU begins trading on NasdaqListing
2 Feb 2026IPO closed with full over-allotment ($57.5M); private placement $1.86MTrust funded at $10.00/share
3–4 Feb 2026$1.48M released to operations; $0.80M sponsor note repaidLiquidity management
5 Feb 2026Audited IPO balance sheet filed; going-concern doubt notedStandard SPAC disclosure, but highlights the $1.77M working-capital deficit
27 Feb 2026MOU with Starcoin Group (HKEX: 0399); Starcoin shares rose sharply intraday on the newsFirst target engagement, within 4 weeks of IPO
10 Mar 2026MOU replaced by tripartite MOU adding Conflux FoundationTarget concept widens into blockchain
~Mar 2026Separate trading of NBRG and NBRGR beginsLiquidity for shares and rights
23 Mar 2026FY2025 10-K filed (7,546,250 shares outstanding)Annual reporting
~May 2026Q1 2026 10-Q filedRoutine
3 Aug 2026BCA with Startech Group Inc. ($1.0B); 8-K/425 and joint press releaseTransformational; pivot away from Starcoin
3–4 Aug 2026NBRG trades about $10.00, essentially flat after announcementMarket treating NBRG as a trust-value instrument, not a growth equity
Aug 2026Independent commentary (remio.ai) questions the thin disclosure on Startech, the AI-plus-water combination, and the sequence after the abandoned Starcoin MOUSentiment and diligence risk
~7 Aug 2026Q2 2026 10-Q filed: H1 net income $385,352; total assets $59.93MTrust income now exceeds costs
~6 Sep 2026Implied lapse of the Starcoin/Conflux MOU's 180-day term (unconfirmed)Cleans up competing target exposure
~2 Oct 2026Deadline for Startech's audited FY2026 financials (status unconfirmed)Gating item for S-4 filing

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment (USD) (FY2024–FY2025): Single segment formation and operating costs rose from USD 140,962 in FY2024 to USD 221,014 in FY2025.
Newbridge Acquisition Limited — Revenue by Segment (USD) (FY2024–FY2025)
Series (USD)FY2024FY2025
Single segment formation and operating costs140,962221,014
Single segment net loss-140,962-221,014

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.